Fosun Attends CIIE for the Seventh Time - Guo Guangchang: Confident that China's High-Level Openness is a Historical Opportunity
Fosun participated in the 7th China International Import Expo (CIIE), showcasing its latest healthcare innovations at the Fosun Pharma booth. The company highlighted several breakthrough products, including the Ion Robotic Bronchoscopy system, which received domestic approval in March 2024 and completed its first commercial application in September. The company also presented the new V2 model of the Exablate Neuro FUS system for treating neurological disorders. Fosun's participation has helped transform many exhibits into market-ready products, with the company investing RMB 3.5 billion in technological innovation in the first half of the year.
Fosun ha partecipato al 7° China International Import Expo (CIIE), presentando le sue ultime innovazioni nel settore della salute presso lo stand di Fosun Pharma. L'azienda ha evidenziato diversi prodotti rivoluzionari, tra cui il sistema di Broncoscopia Robotica Ion, che ha ricevuto l'approvazione nazionale a marzo 2024 e ha completato la sua prima applicazione commerciale a settembre. L'azienda ha anche presentato il nuovo modello V2 del sistema Exablate Neuro FUS per il trattamento dei disturbi neurologici. La partecipazione di Fosun ha contribuito a trasformare molti espositori in prodotti pronti per il mercato, con un investimento di 3,5 miliardi di RMB in innovazione tecnologica nella prima metà dell'anno.
Fosun participó en la 7ª Exposición Internacional de Importaciones de China (CIIE), mostrando sus últimas innovaciones en el sector salud en el stand de Fosun Pharma. La compañía destacó varios productos innovadores, incluyendo el sistema de Broncoscopia Robótica Ion, que recibió la aprobación nacional en marzo de 2024 y completó su primera aplicación comercial en septiembre. La empresa también presentó el nuevo modelo V2 del sistema Exablate Neuro FUS para el tratamiento de trastornos neurológicos. La participación de Fosun ha ayudado a transformar muchas exhibiciones en productos listos para el mercado, con una inversión de 3.5 mil millones de RMB en innovación tecnológica en la primera mitad del año.
포순은 7회 중국 국제 수출 입회(CIIE)에 참여하여 포순 제약 부스에서 최신 건강 관리 혁신을 선보였습니다. 회사는 2024년 3월에 국내 승인을 받은 이온 로봇 기관지경 검사기 시스템을 포함하여 여러 혁신적인 제품을 강조했습니다. 회사는 또한 신경 장애 치료를 위한 엑사블레이트 뉴로 FUS 시스템의 새로운 V2 모델을 발표했습니다. 포순의 참여는 많은 전시품을 시장 출시 가능한 제품으로 전환하는 데 기여하였으며, 올해 상반기에 기술 혁신에 35억 위안을 투자했습니다.
Fosun a participé à la 7e Exposition Internationale d'Importations de Chine (CIIE), présentant ses dernières innovations en matière de santé au stand de Fosun Pharma. L'entreprise a mis en avant plusieurs produits novateurs, notamment le système de Bronchoscopie Robotique Ion, qui a reçu l'approbation nationale en mars 2024 et a réalisé sa première application commerciale en septembre. L'entreprise a également présenté le nouveau modèle V2 du système Exablate Neuro FUS pour le traitement des troubles neurologiques. La participation de Fosun a contribué à transformer de nombreux stands d'exposition en produits prêts pour le marché, l'entreprise ayant investi 3,5 milliards de RMB dans l'innovation technologique au cours de la première moitié de l'année.
Fosun nahm an der 7. China International Import Expo (CIIE) teil und stellte am Stand von Fosun Pharma seine neuesten Gesundheitsinnovationen vor. Das Unternehmen hob mehrere bahnbrechende Produkte hervor, darunter das Ion Roboter-Bronchoskopiesystem, das im März 2024 die nationale Genehmigung erhielt und im September seine erste kommerzielle Anwendung abschloss. Das Unternehmen präsentierte auch das neue V2-Modell des Exablate Neuro FUS-Systems zur Behandlung neurologischer Erkrankungen. Die Teilnahme von Fosun hat dazu beigetragen, viele Ausstellungsstücke in marktfähige Produkte zu verwandeln, wobei das Unternehmen in der ersten Hälfte des Jahres 3,5 Milliarden RMB in technologische Innovation investierte.
- Ion Robotic Bronchoscopy system received domestic approval and completed first commercial application
- 736 Ion systems installed globally with over 150,000 procedures performed
- Establishment of Intuitive Fosun's headquarter industrial base in Shanghai
- RMB 3.5 billion investment in technological innovation in H1
- Yi Kai Da therapy now included in over 110 urban health insurances and available in 170+ treatment centers
- None.
Guo Guangchang, Chairman of Fosun International, remarked, "Over the past seven years, CIIE has improved every year, becoming a window for
Stars of CIIE Taking Root, Transforming Ion from "Exhibit" to "Product"
Healthcare is one of Fosun's main businesses. With CIIE's "spillover effect," several star products from Fosun, supported by the CIIE "accelerator" effect, have successfully entered the market to serve Chinese patients, transforming from "exhibits" into "products". This year, following the popular da Vinci Surgical System, the Ion Robotic Bronchoscopy made its CIIE debut after receiving domestic approval.
Since its first appearance at the CIIE in 2019, Ion caught the attention of visitors. By the end of 2022, Ion entered the National Medical Products Administration's 'Green Channel' for innovative products and gained approval in March 2024, with the first commercial application completed in September.
Lung cancer is considered the leading cause of cancer deaths, with 1.06 million new cases in
Outside the CIIE exhibition hall, Fosun is accelerating the localization of advanced medical devices. In June this year, Intuitive Fosun's headquarter industrial base was launched in
Accelerating Integrated Innovation to Lead in Neurological Disease Treatment Transformation
Fosun has long committed to investing in cutting-edge areas of healthcare, fostering a continuous stream of breakthrough "solid achievements" through an open innovation ecosystem involving independent R&D, collaborative development, licensing, and industry investment. These innovations are continually transformed into new drivers of growth. At this year's CIIE, Fosun introduced several latest products that are leading industry transformation.
In the field of neurological disease treatment, especially for conditions like essential tremor and Parkinson's disease, patients have long faced challenges with unmet clinical needs. Traditional drug and surgical treatments often have limitations, but advancements in non-invasive treatment technologies have brought new hope to these patients.
Fosun has actively responded to this unmet clinical need. At this year's CIIE, the new V2 model of the CNS (Central Nervous System) innovative treatment technology, the V2 model of "Exablate Neuro FUS system" made its debut in
Last year, Fosun, in partnership with Insightec, showcased the "Exablate Neuro" at CIIE, drawing much attention and continuous interest in collaboration. Leveraging the CIIE's "spillover effect", Fosun Pharma and Insightec established a joint venture, Fosun-Insightec, in February this year. The venture is focused on the marketing and developing clinical efforts of Exablate Neuro FUS system in improving the lives of patient living with essential tremor and Parkinson's disease, working to help them regain their quality life and wellbeing.
Focusing on innovating to meet real customer needs is a core methodology for Fosun. Data shows that Fosun has made long-term investments in technological innovation, with an investment of
Connecting Globally to Enhance Accessibility of Innovative Drugs, Benefiting more Patients
Leveraging the CIIE's openness, Fosun also presented innovative products focused on solid tumors, hematological tumors, and immune-inflammatory conditions. Fosun's seven-year journey at CIIE has facilitated the introductions of global products and enabled the export of local innovations to benefit more patients worldwide.
In 2017, Fosun introduced
As a global company rooted in
Guo Guangchang concluded, "Participating in CIIE has been a top priority for Fosun for seven consecutive years. We have witnessed CIIE become a crucial platform for global companies to share in
View original content:https://www.prnewswire.com/news-releases/fosun-attends-ciie-for-the-seventh-time---guo-guangchang-confident-that-chinas-high-level-openness-is-a-historical-opportunity-302298343.html
SOURCE Fosun
FAQ
When did Fosun's Ion Robotic Bronchoscopy system receive approval in China?
How many Ion systems has Fosun (FOSUY) installed globally?
How much did Fosun (FOSUY) invest in technological innovation in the first half of the year?